BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21372305)

  • 1. Visualization of clot lysis in a rat embolic stroke model: application to comparative lytic efficacy.
    Walvick RP; Bråtane BT; Henninger N; Sicard KM; Bouley J; Yu Z; Lo E; Wang X; Fisher M
    Stroke; 2011 Apr; 42(4):1110-5. PubMed ID: 21372305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke.
    Zhu H; Fan X; Yu Z; Liu J; Murata Y; Lu J; Zhao S; Hajjar KA; Lo EH; Wang X
    J Cereb Blood Flow Metab; 2010 Jun; 30(6):1137-46. PubMed ID: 20068577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.
    Lapchak PA; Araujo DM; Song D; Wei J; Zivin JA
    Stroke; 2002 May; 33(5):1411-5. PubMed ID: 11988623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tissue plasminogen activator and annexin A2 combination therapy on long-term neurological outcomes of rat focal embolic stroke.
    Wang X; Fan X; Yu Z; Liao Z; Zhao J; Mandeville E; Guo S; Lo EH; Wang X
    Stroke; 2014 Feb; 45(2):619-22. PubMed ID: 24368559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
    Kajimoto Y; Ohta T; Kuroiwa T
    Neurosurgery; 1997 Mar; 40(3):572-7. PubMed ID: 9055298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annexin A2 Plus Low-Dose Tissue Plasminogen Activator Combination Attenuates Cerebrovascular Dysfunction After Focal Embolic Stroke of Rats.
    Fan X; Jiang Y; Yu Z; Liu Q; Guo S; Sun X; van Leyen K; Ning M; Gao X; Lo EH; Wang X
    Transl Stroke Res; 2017 Dec; 8(6):549-559. PubMed ID: 28580536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early reperfusion rates with IV tPA are determined by CTA clot characteristics.
    Mishra SM; Dykeman J; Sajobi TT; Trivedi A; Almekhlafi M; Sohn SI; Bal S; Qazi E; Calleja A; Eesa M; Goyal M; Demchuk AM; Menon BK
    AJNR Am J Neuroradiol; 2014 Dec; 35(12):2265-72. PubMed ID: 25059699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding.
    Thomas GR; Thibodeaux H; Errett CJ; Badillo JM; Keyt BA; Refino CJ; Zivin JA; Bennett WF
    Stroke; 1994 Oct; 25(10):2072-8; discussion 2078-9. PubMed ID: 8091454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
    Chen HA; Ma YH; Hsu TY; Chen JP
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microfluidic Modeling of Thrombolysis.
    Loyau S; Ho-Tin-Noé B; Bourrienne MC; Boulaftali Y; Jandrot-Perrus M
    Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2626-2637. PubMed ID: 30354249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose tPA plus annexin A2 combination attenuates tPA delayed treatment-associated hemorrhage and improves recovery in rat embolic focal stroke.
    Jiang Y; Fan X; Yu Z; Cheng C; Wang XS; Lo EH; Sun X; Wang X
    Neurosci Lett; 2015 Aug; 602():73-8. PubMed ID: 26149229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
    Zhang Z; Zhang L; Yepes M; Jiang Q; Li Q; Arniego P; Coleman TA; Lawrence DA; Chopp M
    Circulation; 2002 Aug; 106(6):740-5. PubMed ID: 12163437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Imaging of Cerebral Thromboemboli In Vivo: The Effects of Tissue-Type Plasminogen Activator.
    Kim DE; Kim JY; Schellingerhout D; Ryu JH; Lee SK; Jeon S; Lee JS; Kim J; Jang HJ; Park JE; Kim EJ; Kwon IC; Ahn CH; Nahrendorf M; Kim K
    Stroke; 2017 May; 48(5):1376-1385. PubMed ID: 28432262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke.
    Papadopoulos SM; Chandler WF; Salamat MS; Topol EJ; Sackellares JC
    J Neurosurg; 1987 Sep; 67(3):394-8. PubMed ID: 3112328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase.
    Credo RB; Burke SE
    J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):8S-18S. PubMed ID: 8770836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator.
    Lapchak PA; Araujo DM; Song D; Wei J; Purdy R; Zivin JA
    Stroke; 2002 Jun; 33(6):1665-70. PubMed ID: 12053009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke.
    Niessen F; Hilger T; Hoehn M; Hossmann KA
    Stroke; 2003 Aug; 34(8):2019-24. PubMed ID: 12843350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic, organic compound vepoloxamer (P-188) potentiates tissue plasminogen activator.
    Dansdill D; Halandras PM; Beverly J; Jeske W; Hoppensteadt D; Emanuele M; Fareed J; Cho JS
    J Vasc Surg; 2018 Jan; 67(1):294-299. PubMed ID: 27939143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolytic PLGA nanoparticles for slow clot lysis within abdominal aortic aneurysms attenuate proteolytic loss of vascular elastic matrix.
    Sivaraman B; Sylvester A; Ramamurthi A
    Mater Sci Eng C Mater Biol Appl; 2016 Feb; 59():145-156. PubMed ID: 26652359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke.
    Wang C; Huang R; Li C; Lu M; Emanuele M; Zhang ZG; Chopp M; Zhang L
    Stroke; 2019 Dec; 50(12):3600-3608. PubMed ID: 31587657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.